What is the clinical evidence from this study?

Study design: Review. Population: Bradyarrhythmia. Intervention: Leadless pacemakers vs. Conventional transvenous pacemakers.

What does this research mean for the field?

Leadless pacemakers have evolved from a niche solution into a primary therapeutic standard, demonstrating excellent long-term safety and efficacy driven by technological advancements like dual-chamber systems and modular networks. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical safety, efficacy, and technological progression of leadless pacing systems from first-generation devices to modular networks, resynchronization therapies, and novel physiologic sensors.

September 14, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

The Past, Present, and Future of Leadless Pacemakers: A Narrative Review of Technological Evolution and Clinical Evidence

View Full Paper

Ask AI

Bookmark

Key result

Leadless pacemakers resolve long-term pacing morbidities by eliminating transvenous leads and subcutaneous pockets.

Why the study?

Do leadless pacemakers improve safety and efficacy outcomes compared to conventional transvenous pacemakers in patients requiring cardiac pacing?

Key Points

To evaluate the clinical safety, efficacy, and technological progression of leadless pacing systems from first-generation devices to modular networks, resynchronization therapies, and novel physiologic sensors.
Conducted a comprehensive literature search across PubMed, EMBASE, and the Cochrane Library for studies published up to May 2026.
Focused on randomized controlled trials, large prospective registries, and clinical updates evaluating single- and dual-chamber leadless pacing platforms.
Leadless pacemakers systematically eliminated subcutaneous pocket infections and significantly reduced tricuspid valve regurgitation by avoiding transvalvular leads.
Single-capsule mechanical tracking (Micra AV2) yields a projected battery longevity of approximately 15.6 years, whereas dual-chamber conductive communication (AVEIR DR) achieves continuous atrioventricular synchrony exceeding 90% but reduces atrial capsule median longevity to 5.3 years.
Emerging modular systems successfully demonstrate wireless communication between leadless pacemakers and subcutaneous defibrillators, alongside ultrasound acoustic pacing for cardiac resynchronization.

Structured PICO

Do leadless pacemakers improve safety and efficacy outcomes compared to conventional transvenous pacemakers in patients requiring cardiac pacing?

Population

Patients requiring permanent cardiac pacing for bradyarrhythmia management, sinus node dysfunction, or atrioventricular block

Intervention

Leadless pacemakers (LPMs), including single-chamber devices, mechanical atrial tracking systems, and dual-chamber systems utilizing intrabody conductive communication

Comparator

Conventional transvenous pacemakers (TVPs)

Leadless pacemakers have evolved into a primary therapeutic standard that eliminates transvenous lead complications, with future advancements focusing on wireless multi-component networks and energy harvesting.

Limitations

Dual-chamber systems utilizing intrabody conductive communication face severe battery longevity limitations, with the atrial component median lifespan dropping to 5.3 years.
Chronic myocardial encapsulation makes forceful extraction of depleted devices highly hazardous, risking ventricular perforation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support leadless pacemakers to reduce lead complications; leaves open need for RCTs to confirm as standard.

Cite This Study

Sobantka et al. (2026) conducted a review in Bradyarrhythmia. Leadless pacemakers vs. Conventional transvenous pacemakers was evaluated. Leadless pacemakers have successfully transitioned into a primary therapeutic standard that eliminates transvenous leads and subcutaneous pockets, resolving significant long-term pacing morbidities.

synapsesocial.com/papers/6aa7afef79e9260bc85aac91 https://doi.org/10.31435/ijitss.3(51).2026.6676

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

The Past, Present, and Future of Leadless Pacemakers: A Narrative Review of Technological Evolution and Clinical Evidence

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

The Past, Present, and Future of Leadless Pacemakers: A Narrative Review of Technological Evolution and Clinical Evidence

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider